Sintilimab and Cardiovascular Toxicity-Reply

JAMA. 2024 Apr 16;331(15):1334-1335. doi: 10.1001/jama.2024.0676.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized* / adverse effects
  • Antibodies, Monoclonal, Humanized* / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Biomarkers / analysis
  • Cardiovascular Diseases* / chemically induced
  • Cardiovascular Diseases* / diagnosis
  • Cardiovascular System
  • Creatine Kinase, MB Form / analysis
  • Heart
  • Immune Checkpoint Inhibitors* / adverse effects
  • Immune Checkpoint Inhibitors* / therapeutic use
  • Myocarditis / chemically induced
  • Randomized Controlled Trials as Topic

Substances

  • Antibodies, Monoclonal, Humanized
  • sintilimab
  • Creatine Kinase, MB Form
  • Biomarkers
  • Immune Checkpoint Inhibitors